Chief Financial and Corporate Development Officer

Brett is Chief Financial and Corporate Development Officer at Chroma Medicine. He also serves as the Audit Committee Chair of Compass Therapeutics. Prior to joining Chroma, Brett was the Chief Financial Officer of Prevail Therapeutics, which was acquired by Eli Lilly and Company in January 2021 for $940 million. While at Prevail, Brett raised $175 million, including leading the company's $125 million initial public offering. Previously, Brett worked at Evercore, serving as Managing Director involved in numerous strategic and financing transactions, including advising Bristol-Myers Squibb on its acquisitions of Celgene and Amylin, Takeda on its acquisitions of Shire and of Ariad, and the merger of Akebia and Keryx. His previous roles include Equity Research Analyst at Cowen and Company; Director of Corporate Development at Cubist Pharmaceuticals, a pharmaceutical company acquired by Merck & Co., Inc.; Manager of Strategic Medical Marketing at Biopure Corporation; and Manager of Corporate Development and Strategy at Eli Lilly. Brett holds an M.B.B.Ch. and an M.B.A. from the University of Witwatersrand.